Document is current

Article History

Received: 18 April 2026

Accepted: 27 May 2026

First Online: 1 June 2026

Declarations

:

: Approval was obtained from the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Thailand (Certificate of Approval No. 1156/2024). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. The approval of retrieving retrospective data was made and informed consent was waived by the Institutional Review Board.

: Not applicable.

: S.T. reports speaker and advisory board honoraria from BL HUA, DKSH Thailand, Lundbeck, Pfizer Thailand, Viatris, and ZP Therapeutics. A.H. and S.R. report no significant conflict of interest related to this topic. T.P. reports receiving speaker honoraria from BL HUA, Lundbeck, Pfizer Thailand, Daiichi Sankyo, Eisai, Servier, DKSH, and ZP Therapeutics, and advisory board Honoria from BL HUA and Pfizer Thailand. W.R. reports receiving speaker and advisory board honoraria from BL HUA, DKSH Thailand, Lundbeck, Pfizer Thailand, Viatris, and ZP Therapeutics. P.A. reports speaker and advisory board honoraria.